IP/patents

Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.

The collaborators will grant the licenses to any entities wanting to use the technology for commercial agricultural research and product development.

The nonexclusive license allows Arcadia to use the patented technology to develop nutritional and agricultural productivity traits in its core crops.

Enzo Biochem, Enzo Life Sciences, and Yale University had originally brought the suit against Life Technologies, now part of Thermo Fisher, in 2004.

Population Genetics was formed to commercialize the IP portfolio of Sydney Brenner focused on high sensitivity and high specificity NGS detection.

Enzo's patent relates to modified nucleotides for diagnostic and therapeutic applications, and is central to separate ongoing lawsuits with diagnostic developers.

In a recent regulatory filing, Thermo disclosed that it acquired Core Informatics for $94 million and Finesse Solutions for $220 million.

The IP stems from the work of Anjana Rao, who identified 5-hydroxymethylcytosine (5hmC) as a cancer diagnostic biomarker.

PacBio alleged in its suit that Oxford Nanopore is infringing on a patent it holds related to single-molecule nanopore sequencing.  

Agilent filed a lawsuit against Twist nearly a year ago, alleging that Twist Cofounder and CEO Emily LeProust had stolen DNA oligonucleotide synthesis technology. 

Pages

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.